Dyspepsia is a problem commonly seen by primary
|
|
- Pierce Bishop
- 5 years ago
- Views:
Transcription
1 Concise Review for Clinicians Nonulcer Dyspepsia: What It Is and What It Is Not G. RICHARD LOCKE III, MD Nonulcer dyspepsiais a description of persistent or recurrent upper abdominal pain or discomfort with no structural or biochemical explanation for the patient's symptoms. The exact cause of nonulcer dyspepsia is not known, but many myths have evolved regarding its etiology and treatment. The goal of this reviewis to evaluate the potential causesof nonulcer dyspepsia.bydetermining what it is Dyspepsia is a problem commonly seen by primary care physicians. Most patients with dyspepsia do not have ulcers or cancers. In fact, the majority do not have a structural or biochemical explanation for their symptoms. Such patients are diagnosed as having nonulcer dyspepsia (NUD). Multiple potential pathogeneses have been postulated for NUD. Similarly, many different therapies have been tried. This multitude of diagnostic and therapeutic options simply underscores the fact that the true cause of dyspepsia is not known. At present, there is no clear consensus as to how best to manage patients with NUD. The goal of this article is to review the etiologic and therapeutic options and recommend management approaches for this common condition. DEFINITION Dyspepsia is not a condition, it is a symptom complex. Dyspepsia can be defined as persistent or recurrent abdominal pain or abdominal discomfort centered in the upper abdomen. I This discomfort may include symptoms of nausea, vomiting, early satiety, postprandial fullness, and upper abdominal bloating. Symptoms are typically associated with eating but not with bowel movements. Heartburn and acid regurgitation are often included as symptoms of dyspepsia; yet if these are the main symptoms, the patient should be considered to have reflux rather than dyspepsia. Patients with symptoms or signs typical of biliary tract or pancreatic disease should not be considered to have NUD. From the Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic Rochester, Rochester, Minn. Dr Locke is the recipient of an American College of Gastroenterology Institute Junior Faculty Development Award. Address reprint requests and correspondence to G. Richard Locke III, MD, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, 200 First St SW, Rochester, MN Mayo Clin Proc. 1999;74: and what it is not, we can be more selective in our approach to diagnosisand our choiceof empiric therapies. Mayo Clin Proc. 1999;74: GERD =gastroesophageal reflux disease; NSAIDs =nonsteroidal anti-inflammatory drugs; NUD = nonulcer dyspepsia; PUD =peptic ulcer disease Thus, right upper quadrant pain or epigastric pain radiating to the back should not be included in the definition of dyspepsia. Nonulcer dyspepsia can then be defined as dyspepsia symptoms of more than 3 months' duration without an anatomical or biochemical abnormality. Typically, this means normal blood test results and a negative evaluation of the upper gastrointestinal tract with either endoscopy or barium radiography. However, defining a negative endoscopy can be difficult. Does this include biopsies of the esophagus for esophagitis or biopsies of the stomach for gastritis or Helicobacter pylori infection? Are erythema, erosions, or histologic inflammation meaningful findings? These controversial issues are discussed subsequently. What about other diagnostic tests such as ultrasonography, computed tomographic scans, gastric-emptying studies, or ambulatory ph monitoring? Do these have to be done before a diagnosis of NUD is made? These are the issues that need to be addressed. EPIDEMIOLOGY Many surveys have evaluated how many people experience symptoms of dyspepsia in the community. The rates vary in large part because of the definitions used. Some surveys include the symptom of heartburn in the definition of dyspepsia and report a prevalence of 40%. Other surveys exclude subjects with symptoms of heartburn or irritable bowel syndrome and report prevalence rates of less than 5%. Nonetheless, it is probably reasonable to estimate that 15% (about 1 in 7) of the adult population has dyspepsia.' Not all these people have NUD, however. In 1 study, a random sample of the population with dyspepsia underwent endoscopy"; 53% had normal endoscopy. The remarkable findings were esophagitis, peptic ulcer disease (PUD), duodenitis, and duodenogastric reflux. Of note, only 66% of the asymptomatic controls in this study had 1999 Mayo Foundation/or Medical Education and Research
2 1012 Nonulcer Dyspepsia normal endoscopic findings. Only PUD and duodenitis were more common in the patients with dyspepsia than in the controls. Dyspepsia accounts for a significant number of medical visits. Unfortunately, the National Center for Health Statistics does not use a specific code for dyspepsia. More than 2 million office visits occur each year for gastritis and duodenitis, and most of these are to general practitioners and internists. In 1 study, patients presenting to primary care physicians with dyspepsia underwent endoscopy prior to therapy.' Twenty-two percent had peptic ulcer disease, 10% had esophagitis, 1% had cancer, and the remaining 67% had NUD. To summarize, symptoms of dyspepsia are common and result in a high number of physician visits. Most people presenting with dyspepsia have negative evaluations, and thus, they are diagnosed as having NUD. WHAT IT IS AND WHAT IT IS NOT Table I lists the most frequently mentioned etiologic possibilities for NUD. In some ways, the thinking has been divided into 2 worlds: patients have either an acid or H pylori problem or a motility disorder. This led investigators to try to identify specific symptom subtypes such as reflux-like, ulcer-like, or dysmotility-like dyspepsia. The idea was that symptoms of dyspepsia could result from multiple etiologies; however, by refining the symptom criteria, more specific etiologies would be identified. Although the reasoning was sound, this has not proved true. Symptoms and specific test findings do not correlate well, and this is just 1 of the problems in identifying the cause of NUD. Table 2 lists some others. The clinician must be careful before attributing any cause-and-effect relationship. Is NUD Caused by Gastritis or H pylorn Traditional teaching in the 1980s was that the differential diagnosis of dyspepsia included PUD, esophagitis, gastric cancer, and gastritis. Patients were empirically treated with acid inhibitors as these were thought to be effective for the 3 benign conditions. However, the identification of H pylori has forced reanalysis of this issue. Fifty percent of adults older than 60 years are infected with H pylori. The rates are lower in younger people, closer to 15%. H pylori infection is synonymous with type B chronic active gastritis. Thus, most of the elderly have gastritis, yet they do not all have symptoms of dyspepsia. In the communitybased endoscopy study mentioned previously,' the majority of asymptomatic controls had histologically proved gastritis. The prevalence of gastritis was only slightly more common in dyspeptic patients. Still, the idea that the histologic inflammation gives rise to symptoms is an interesting Mayo Clin Proc, October 1999, Vol 74 Table 1. Nonulcer Dyspepsia: The Possibilities Acid-H pylori H pylori infection Gastritis, duodenitis Overlooked peptic ulcer disease Acid sensitivity Occult gastroesophageal reflux disease Motility Gastroparesis Abnormal relaxation Visceral hypersensitivity Brain-gut disorder Psychological disorder one. The early findings and reports of H pylori eradication in NUD disagreed. Examination of specific subtypes of H pylori, such as those that express the CagA gene, has not clarified this issue. Fortunately, 2 multicenter, placebocontrolled clinical trials were recently ' published.v" In both studies, 20% of the subjects had resolution of their dyspeptic symptoms at I year. What differed between the studies was the placebo response rate, which was 20% in I study and 8% in the other. Therefore, the 2 studies came to conflicting conclusions. Thus, the role of H pylori eradication in the treatment of NUD remains controversial. Since H pylori treatment may help one fifth of patients and H pylori has been declared a carcinogen by the World Health Organization, this treatment remains worthy of consideration. Although the role of H pylori in NUD is controversial, its role in PUD is clear. At times, however, the boundary between PUD and NUD becomes fuzzy. Specifically, some patients have duodenitis or duodenal erosions. They may have a history of PUD but negative endoscopic findings at the time of presentation. Overall, these patients should be managed as having PUD rather than NUD. Many patients have minor erosions or erythema of the stomach at endoscopy. The endoscopist cannot distinguish whether this represents gastritis or gastropathy. The determination requires histologic evaluation. Gastropathy is primarily associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs). The role of NSAIDs, like that of H pylori, in causing dyspepsia without PUD is somewhat controversial. NSAIDs certainly cause erosions, many of which are asymptomatic. The development of dyspepsia in NSAID users is associated with psychological distress. Patients who take NSAIDs and have gastric erosions can still be considered to have NUD. Typically, when patients develop dyspepsia while taking NSAIDs, the NSAID is temporarily discontinued to see if the dyspepsia resolves.
3 Mayo Clio Proc, October 1999, Vol 74 Is NUD an Acid Problem? Patients commonly take antacids for relief of dyspepsia, yet gastric acid secretion is normal in patients with NUD. One hypothesis is that patients with NUD may be more sensitive to acid. However, studies in which acid secretion has been stimulated with pentagastrin have yielded conflicting results. Other investigators infused acid or saline directly into the stomach in a blinded fashion, and these results were also conflicting. Placebo-controlled trials have not shown that antacids are more effective than placebo in relieving NUD. However, since patients can take antacids on their own, those who seek medical care may be those for whom the antacids were not helpful. Similarly, histamine receptor antagonists have been used widely in the treatment of NUD. A meta-analysis done in 1989 reported that histamine blockers had a mean success rate 20% higher than placebo.' Are proton pump inhibitors any better? The data on proton pump inhibition and NUD are mostly directed toward H pylori eradication. In 1 of the H pylori eradication trials mentioned previously, omeprazole was used with antibiotic placebos, and 8% of patients were symptom free at 1 year. The omeprazole, however, was given for only 4 weeks. Thus, the role of proton pump inhibitor therapy in NUD is not clear. Is NUD Occult Gastroesophageal Reflux? Gastroesophageal reflux disease (GERD) encompasses all the manifestations of gastric acid moving into the esophagus. The typical symptoms of reflux are heartburn and acid regurgitation. These symptoms are experienced by 20% of the population on a weekly basis. Some investigators include these symptoms in their definition of dyspepsia (reflux-like dyspepsia). Others believe that this is inappropriate. Patients with typical symptoms of heartburn or acid regurgitation are usually treated empirically without investigation and should be considered to have GERD. However, not all patients with GERD have typical symptoms. Studies have performed ambulatory ph monitoring in patients with epigastric pain and found that 50% to 60% have excessive acid exposure. Thus, there is likely a subset of dyspeptic patients who do, in fact, have occult GERD. Unfortunately, these patents are difficult to identify. Ambulatory ph monitoring may be considered, or alternatively, empiric treatment trials directed toward reflux can be used. 'S NUD a Motility Disorder? Although clinicians often focus on epigastric pain as the cardinal symptom of NUD, most investigators include other symptoms such as nausea, fullness, early satiety, and the like. These symptoms suggest that motor abnormalities Nooulcer Dyspepsia 1013 Table 2. Nonulcer Dyspepsia: The Problems Symptomscome and go (and change) Placebo response rate is high (30%+) No findings are present in all patients with nonulcer dyspepsia Findings are present in asymptomatic patients Symptoms and findings do not correlate No therapy is universallyeffective Response to therapy is hard to predict may play a role in this condition. Between one third and one half of patients with NUD seen in the gastroenterology clinics of referral centers will have delayed gastric emptying. Multiple studies, primarily in Europe, have evaluated the role of prokinetics in NUD. In general, prokinetics are 30% more effective than placebo, although the rates between studies have been quite variable. Only 1 study has directly compared a prokinetic with a histamine blocker, and the prokinetic was slightly more effective." Most of the studies have been with cisapride at low doses (10 mg, 2 to 4 times daily). Domperidone is available in Europe but not in the United States. Metoclopramide has been shown to be helpful, which may in part be due to its antiemetic effects. Still, long-term use of metoclopramide needs to be avoided because of the risk of tardive dyskinesia. Recently, the prokinetic agent cisapride has been associated with torsades de pointes. Thus, electrocardiographic monitoring and careful consideration of drug-drug interactions have become necessary. More recently, attention has shifted from gastric emptying to gastric accommodation. That is, just like the heart, the stomach has both systolic and diastolic functions. Recent studies have shown that gastric accommodation (the relaxation of the stomach in response to a meal) is abnormal in patients with functional dyspepsia." Medications such as nitroglycerin, calcium channel blockers, and anticholinergics are being evaluated to see if they improve the accommodation response. However, at present their effectiveness is not known. Is NUD a Functional Disorder? The functional disorders are a continuum of illnesses characterized by gastrointestinal symptoms with negative diagnostic evaluations. There is significant overlap among these disorders.'? Specifically, at least one third of people with NUD also have symptoms of irritable bowel syndrome, including a lower threshold for rectal distention. In NUD, a similar phenomenon is noted for distention of the stomach. Patients with NUD report pain at a lower volume when a gastric balloon is inflated in the gastric cavity. More recently, central nervous system imaging has highlighted
4 Mayo Clin Proc, October 1999, Vol Nonulcer Dyspepsia the activation of different parts of the brain in subjects with functional gastrointestinal disorders. Thus, the concept of visceral hypersensitivity remains a strong consideration in all functional gastrointestinal disorders, including NUD. At present, however, there is not a specific medication for visceral hypersensitivity, although newer agents such as fedotozine and serotonin receptor antagonists are being investigated. Clinically, low-dose antidepressants are being used, although formal clinical trial data are lacking. Is NUD a Psychiatric Disease? Like the other functional gastrointestinal disorders, patients with NUD do report higher levels of psychological distress as well as higher rates of anxiety and depression. The question remains as to whether the psychiatric distress is the cause of the NUD or rather promotes health care-seeking behavior. Psychological and psychiatric interventions are being investigated in NUD, although, once again, clinical trial data are not yet available. Furthermore, there is little benefit in arguing with the patient whether the NUD is organic or psychiatric. Clinicians need to take the patient's symptoms seriously; however, if a psychiatric disease is present, it needs to be treated, and this may affect the gastrointestinal symptoms. diagnostic testing or referral to a gastroenterologist may be considered. Tests to consider include abdominal imaging with computed tomography or ultrasonography, gastric emptying studies, or ambulatory ph monitoring. In the future, simpler tests of gastric function may become available. Often the diagnostic tests can be interfaced with therapeutic trials of H pylori eradication, proton pump inhibitors, prokinetics, mucosal protectants such as sucralfate, anticholinergics, or, finally, use of low-dose antidepressants. In one third to one half of patients with dyspepsia, symptoms resolve spontaneously. Yet, some will be plagued by this problem chronically. The hope for the future is that new medications to treat visceral hypersensitivity or gastric accommodation prove useful and strengthen the clinician's armamentarium against this common disorder. ACKNOWLEDGMENT I wish to thank Karen A. Kruger for her assistance in preparing the submitted manuscript. REFERENCES I. Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyren 0, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int. 1991;4: 2. Locke GR III. Prevalence, incidence and natural history of dyspepsia and functional dyspepsia. Bail/ieres Clin Gastroenterol. 3. Johnsen R, Bemersen B, Straume B, Forde OH, Bostad L, Burhol PG. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ. 1991;302: Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H,-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet. 1994;343: Blum AL, Talley NJ, O'Moniin C, et al, Omeprazole Plus Clarithromycin and Amoxicillin Effect One Year After Treatment (OCAY) Study Group. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. RECOMMENDATIONS FOR EVALUATION AND THERAPY Given all the controversy with conflicting study results and inadequate data, how is the clinician to proceed? By definition, patients with NUD have a diagnostic evaluation, either upper gastrointestinal tract radiography or endoscopy, to exclude PUD and malignancy. Since current practice guidelines recommend either a trial of acid inhibition or testing for H pylori prior to any diagnostic investigation for dyspepsia, most patients have I or both of these done prior to the diagnosis of NUD. The first step is to provide reassurance. Some patients with NUD simply want to be sure they do not have cancer. They find their symptoms tolerable and require no further intervention. The most difficult decision is whether to perform further diagnostic testing. The alternative is to proceed directly with empirical treatment trials. Initially, investigators hoped that symptom subgroups of dyspepsia such as motility-like, ulcer-like, or reflux-like groups could be identified, and this would help guide decisions. To date, however, these subgroups have not proven useful. At present, the decision regarding diagnostic tests vs treatment trials depends on the patient's preferences and the physician's practice style. If the physician and patient are comfortable with the diagnosis of NUD, then diagnostic testing can be kept to a minimum. However, if either party is uncertain, then further ; 12: ;339: McColl K, Murray L, El-Omar E, et a1. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339: Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia: a meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol. 1989;11: Finney JS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol. 1998;26: Camilleri M. Nonulcer dyspepsia: a look into the future. Mayo Clin Proc. 1996;71: Agreus L, Svardsudd K, Nyren 0, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:
5 Mayo Clin Proc, October 1999, Vol 74 Nonulcer Dyspepsia 1015 Questions About Nonulcer Dyspepsia (See article, pages 1011 to 1014) 1. What percentage of patients presenting with symptoms of dyspepsia have NUD? a.5% b. 15% c. 33% d.67% e. 85% 2. What percentage of elderly patients have histologically proved gastritis? a. 0% to 1% b. 5% to 10% c. 20% to 30% d. 50% to 70% e. 90% to 100% 3. Which one of the following is the first step in the management of a patient with NUD? a. Provide reassurance b. Order additional imaging studies c. Initiate empiric treatment d. Refer to a gastroenterologist e. Refer to a psychiatrist 4. Which one of the following is found in less than 10% of patients presenting with dyspepsia? a. H pylori infection b. Delayed gastric emptying c. Excess gastric acid production d. Symptoms of irritable bowel syndrome e. Gastroesophageal reflux on ph monitoring 5. Which one of the following treatments has not been shown to be effective in some patients with NUD? a. Histamine receptor antagonists b. Prokinetics c. H pylori eradication regimens d. Low-dose tricyclic antidepressants e. Calcium channel blockers Correct answers: a. d, 2. d, 3. a, 4. c, 5. e
Clinical Evaluation of Himcocid Suspension in Patients with Non-ulcer Dyspepsia
[The Antiseptic (21): (98), 11, 49-411] Clinical Evaluation of Himcocid Suspension in Patients with Non-ulcer Dyspepsia Upadhyaya, B.N., Reader and Head, and Khagen Basumathy, Junior Resident Department
More informationCHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University
CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University 1 Definition of FGID Chronic and recurrent symptoms of the gastrointestinal
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationFunctional Dyspepsia. Norbert Welkovics Heine van der Walt
Norbert Welkovics Heine van der Walt Characteristics: Central abdomen Pain or discomfort Not associated with bowel movements No structural or biochemical abnormalty Definition Part of Gastroduodenal disorders
More informationOutline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationNumber of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI
Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review
More informationFunctional Heartburn and Dyspepsia
Functional Heartburn and Dyspepsia Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina Objectives Understand the means of diagnosing functional heartburn
More information6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other
Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of
More informationThe PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures
The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationFunctional Dyspepsia
Linköping University Medical Dissertations No. 792 Functional Dyspepsia Symptoms and Response to Omeprazole in the Short Term by Elisabeth Bolling-Sternevald Department of Biomedicine and Surgery, Faculty
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationFecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
More informationOne-third of adults experience pain or discomfort in
GASTROENTEROLOGY 2002;122:1270 1285 Dyspepsia Management in Primary Care: A Decision Analysis of Competing Strategies BRENNAN M. R. SPIEGEL,* NIMISH B. VAKIL, and JOSHUA J. OFMAN*, *Department of Medicine
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More informationHealth-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia
Aliment Pharmacol Ther 23; 17: 835 84. doi: 1.146/j.269-2813.23.1497.x Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia A. QUADRI & N. VAKIL University of Wisconsin
More informationManagement of dyspepsia in adults in primary care
Dyspepsia Management of dyspepsia in adults in primary care June 2005. The recommendations on referral for endoscopy in this NICE guideline have been amended in line with the recommendation in the NICE
More informationThe Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 160-164 ORiginal Article The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationClinical Trial of Efcid (Himcocid) in Patients of Acid Peptic Disease
[The Antiseptic (2001): (98), 2, 50] Clinical Trial of Efcid (Himcocid) in Patients of Acid Peptic Disease Rangamani, K., Professor of Medicine, Bowring and Lady Curzon Hospitals, Shivajinagar, Bangalore,
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationHELICOBACTER PYLORI; PATIENTS WITH FUNCTIONAL DYSPEPSIA
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-2404 1. Associate Professor and Health Sciences, (LUMHS) 2. MD, Consultant Physician,, Medical-III, Ward 06 Liaquat University Hospital,
More informationDefinition, Pathogenesis, and Management of That Cursed Dyspepsia
Clinical Gastroenterology and Hepatology 2018;16:467 479 Definition, Pathogenesis, and Management of That Cursed Dyspepsia Pramoda Koduru, Malcolm Irani, and Eamonn M. M. Quigley IM F1 김영기 Dyspepsia Umbrella
More informationApproaches to uninvestigated dyspepsia
iv42 DYSPEPSIA MANAGEMENT Approaches to uninvestigated dyspepsia R H Jones... Uninvestigated dyspepsia refers to patients with new or recurrent dyspeptic symptoms in whom no investigations have previously
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationSASKATCHEWAN REGISTERED NURSES ASSOCIATION
DEFINITION Reflux of gastric contents into the esophagus, which results in esophageal irritation or inflammation. IMMEDIATE CONSULTATION REQUIRED IN THE FOLLOWING SITUATIONS Dysphagia (solid food, progressive)
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationMANAGEMENT OF DYSPEPSIA
Review Article MANAGEMENT OF DYSPEPSIA Raeefuddin Ahmed* SUMMARY Upper gastro-intestinal motility disorders are not uncommon. While the exact prevalence in Pakistan is not known there are substantial number
More informationOriginal Article. Rattanasupar A Attasaranya S Ovartlarnporn B ABSTRACT
74 THAI J GASTROENTEROL 2010 Esophagogastroduodenoscopy (EGD) plus Transabdominal Ultrasound (TUS) for Diagnosed Dyspepsia in Elderly Patients Original Article Esophagogastroduodenoscopy (EGD) plus Transabdominal
More informationFunctional dyspepsia: recent advances in pathophysiology. Citation Hong Kong Practitioner, 1998, v. 20 n. 6, p
Title Functional dyspepsia: recent advances in pathophysiology Author(s) Hu, HC; Lam, SK Citation Hong Kong Practitioner, 1998, v. 20 n. 6, p. 327-334 Issued Date 1998 URL http://hdl.handle.net/10722/45089
More informationUrea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013
MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationValidation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia
Aliment Pharmacol Ther 2005; 22: 357 363. doi: 10.1111/j.1365-2036.2005.02572.x Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia B.
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationDyspepsia and upper gastrointestinal bleeding. Dr. Wayne H.C. Hu 胡興正
Dyspepsia and upper gastrointestinal bleeding Dr. Wayne H.C. Hu 胡興正 25 year old medical student Occasional smoker and drinker. About to take final examinations. 3 week history of epigastric bloating. Worse
More informationACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease
ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein
More informationReflux of gastric contents, particularly acid, into the esophagus
Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationKEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.
INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY Karunamoorthy Rajachidambaram 1, Dinkaran Kaarthesan
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationA Placebo-Controlled Trial of Itopride in Functional Dyspepsia
The new england journal of medicine original article A Placebo-Controlled Trial of Itopride in Functional Dyspepsia Gerald Holtmann, M.D., Nicholas J. Talley, M.D., Ph.D., Tobias Liebregts, M.D., Birgit
More informationGastroenterology Fellowship Program
Gastroenterology Fellowship Program Outpatient Clinical Rotations I. Overview A. Three Year Continuity Clinic Experience All gastroenterology fellows will be required to have a ½ day continuity clinic
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More information1. Appropriateness of Gastroscopy: Dyspepsia 1
Special Topic 579 1. Appropriateness of Gastroscopy: Dyspepsia 1 F. Froehlich *, M. Bochud **, J.-J. Gonvers*, R.W. Dubois***, J.-P. Vader **, V. Wietlisbach ***, B. Burnand ** * Policlinique Médicale
More informationManagement of Functional Dyspepsia (FD)
Management of Functional Dyspepsia (FD) Amy S. Oxentenko, MD, FACG Program Director and Associate Chair, IM Associate Professor of Medicine Mayo Clinic, Rochester Outline Define functional dyspepsia (FD)
More informationreceptor antagonists and prokinetics in dyspepsia: a critical review
iv58 DYSPEPSIA MANAGEMENT H 2 antagonists and prokinetics in dyspepsia: a critical review P Bytzer... Drug treatment of with functional dyspepsia is controversial but H 2 antagonists have been the mainstay
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationInvestigating dyspepsia Rocco Maurizio Zagari, Lorenzo Fuccio, Franco Bazzoli
DATE: 11/5/2008-10:27:27 ID:(BMJ)zagr584193 /(Jouve)bmj-001985 DOI: 10.1136/bmj.a1400 Topic(s): Type: InSection:review-article For the full versions of these articles see bmj.com CLINICAL REVIEW Investigating
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationTBURN TBURN BURN ARTBURN EARTBURN EART HEARTBURN: HOW TO GET IT OFF YOUR CHEST
TBURN BURN TBURN ARTBURN. EARTBURN EART N EARTBURN HEARTBURN: HOW TO GET IT OFF YOUR CHEST Do you sometimes wake up at night with a sharp, burning sensation in your chest? Does this sometimes happen during
More informationD yspepsia literally means bad digestion. Evaluation and treatment of dyspepsia REVIEW. M P Jones...
25 REVIEW Evaluation and treatment of dyspepsia M P Jones... Dyspepsia is a common symptom. Dyspeptic symptoms may be caused by a variety of conditions such as peptic ulcer disease, gastro-oesophageal
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 339 D ECEMBER 24, 1998 NUMBER 26 SYMPTOMATIC BENEFIT FROM ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS
More informationSecond term/
Second term/ 2015-2016 L. 1 Dr Mohammed AL-Zobaidy Learning objectives GIT pharmacology After completing this chapter the student will be able to: Recognise pathophysiological factors implicated in acid-peptic
More informationFigure 2: Post-cholecystectomy biliary-like pain
Figure 2: Post-cholecystectomy biliary-like pain 1 patient with recurrent episodes of pain (not daily), in the epigastrium/right upper quadrant, lasting >30 mins, building to a steady level, interrupting
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationGastroesophageal Reflux Disease, Paraesophageal Hernias &
530.81 553.3 & 530.00 43289, 43659 1043432842, MD Assistant Clinical Professor of Surgery, UH JABSOM Associate General Surgery Program Director Director of Minimally Invasive & Bariatric Surgery Programs
More informationA Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori- Negative Primary Care Patients with Dyspepsia in Japan
Gut and Liver, Vol. 7, No. 1, January 2013, pp. 16-22 ORiginal Article A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori- Negative Primary Care Patients with Dyspepsia in Japan Tomoari
More informationGastroenterology. Certification Examination Blueprint. Purpose of the exam
Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist
More informationORIGINAL INVESTIGATION. Lack of Effect of Treatment for Helicobacter pylori on Symptoms of Nonulcer Dyspepsia
Lack of Effect of Treatment for Helicobacter pylori on Symptoms of Nonulcer Dyspepsia Paul D. Greenberg, MD; John P. Cello, MD ORIGINAL INVESTIGATION Background: Prior studies have yielded conflicting
More informationSpeaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015
GERD: Who and When to Treat Eugenio J Hernandez, MD Gastrohealth, PL Assistant Professor of Clinical Medicine, FIU Herbert Wertheim School of Medicine Speaker disclosure I do not have any relevant commercial
More informationModule 2 Heartburn Glossary
Absorption Antacids Antibiotic Module 2 Heartburn Glossary Barrett s oesophagus Bloating Body mass index Burping Chief cells Colon Digestion Endoscopy Enteroendocrine cells Epiglottis Epithelium Absorption
More informationTreatment of H. pylori Infection: The Reality
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee
More informationFEDERAL BUREAU OF PRISONS CLINICAL PRACTICE GUIDELINES GASTROESOPHAGEAL REFLUX DISEASE (GERD) DYSPEPSIA, AND PEPTIC ULCER DISEASE, NOVEMBER, 2001
FEDERAL BUREAU OF PRISONS CLINICAL PRACTICE GUIDELINES GASTROESOPHAGEAL REFLUX DISEASE (GERD) DYSPEPSIA, AND PEPTIC ULCER DISEASE, NOVEMBER, 2001 PURPOSE The Federal Bureau of Prisons Clinical Practice
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationDyspepsia: management guidelines for the millennium
iv72 DYSPEPSIA MANAGEMENT Dyspepsia: management guidelines for the millennium N J Talley... The annual prevalence of dyspepsia in Western countries is approximately 25%, and the condition accounts for
More informationOur evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders.
Our evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders. SmartPill benefits your practice: Convenient performed right in your office Test standardization Provides direct
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationDigestion. Text. What You Don t Know Can Hurt You!
Digestion Text What You Don t Know Can Hurt You! Digestive Problems Approximately 36.5 million visits annually to ambulatory care facilities due to the diseases of the digestive system Over 4 million ulcers
More informationFEATURE ARTICLE DYSPEPSIA MANAGEMENT IN A RESOURCE POOR SETTING
FEATURE ARTICLE DYSPEPSIA MANAGEMENT IN A RESOURCE POOR SETTING A.C. Jemilohun 1 and J.O. Fadare 2 Ann Ibd. Pg. Med 2013. Vol.11, No.1 2-6 1. Department of Medicine, Ladoke Akintola University of Technology,
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationAchalasia is a rare disease with an annual incidence estimated REVIEWS. Erroneous Diagnosis of Gastroesophageal Reflux Disease in Achalasia
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:1020 1024 REVIEWS Erroneous Diagnosis of Gastroesophageal Reflux Disease in Achalasia BOUDEWIJN F. KESSING, ALBERT J. BREDENOORD, and ANDRÉ J. P. M. SMOUT
More informationSUPPLEMENTARY INFORMATION Associated with
Table1: Rome III and Rome IV diagnostic criteria for IBS, functional constipation and functional dyspepsia. Rome III diagnostic criteria 1,2 Rome IV diagnostic criteria 3,4 Diagnostic criteria for IBS
More informationZantac for stomach ulcers
P ford residence southampton, ny Zantac for stomach ulcers Information on the drug ranitidine (Zantac) used in and duodenal ulcers, heartburn, esophagitis, and Zollinger Ellison Syndrome. Side. But with
More informationACG and CAG Clinical Guideline: Management of Dyspepsia
988 CLINICAL GUIDELINES CME ACG and CAG Clinical Guideline: Management of Dyspepsia Paul M. Moayyedi, MB, ChB, PhD, MPH, FACG 1, Brian E. Lacy, MD, PhD, FACG 2, Christopher N. Andrews, MD 3, Robert A.
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationDyspepsia: alarm symptoms, investigation and management
Drug review Dyspepsia Dyspepsia: alarm symptoms, investigation and management SPL Steven Fong MRCP and Jason Dunn PhD, MRCP Dyspepsia is a common symptom and the priority is to identify alarm signals that
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGastroesophageal Reflux Disease in Infants and Children
Gastroesophageal Reflux Disease in Infants and Children 4 Marzo 2017 Drssa Chiara Leoni Drssa Valentina Giorgio pediatriagastro@gmail.com valentinagiorgio1@gmail.com Definitions: GER GER is the passage
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology Faculty representative: David L. Burns, MD, CNSP Resident representative: Tom Castiglione, MD Revision date: March 6, 2006
More informationDYSPEPSIA is a common problem that often leads to consultation
Original papers A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome Nicoline T Lewin-van den Broek, Mattijs E Numans,
More informationAn Approach to Abdominal Pain
An Approach to Abdominal Pain objectives Should know the different types of abd pain Is acute or chronic? Hx taking skills with knowing the key questions Important abdominal pain signs A good differential
More informationGASTRIC EMPTYING STUDY (SOLID)
GASTRIC EMPTYING STUDY (SOLID) Aim To evaluate patients with symptoms of altered of gastric emptying and/or motility, and quantitatively measure the rate of gastric emptying. This study provides a physiologic,
More informationEsophageal Disorders. Learning Objectives. Introduction. Gastroesophageal Reflux Disease. Reza Shaker, MD, and Benson T.
Esophageal Disorders Reza Shaker, MD, and Benson T. Massey, MD, FACP Learning Objectives AFTER COMPLETING THIS CHAPTER, THE LEARNER SHOULD BE ABLE TO: 1. Recognize the typical and atypical presentations
More information